Urinary biomarker test and real-world use of SGLT2 inhibitors in CKD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, real-world observational study in adults with CKD stages 2–4. It follows patients who start an SGLT2 inhibitor (empagliflozin) and matched controls over 12 months, using electronic health records and lab data. The study also aims to validate a urinary biomarker panel for early CKD detection and progression monitoring. No new treatments are assigned by the study; it observes real-world practice and outcomes. Primary outcome is the annual rate of eGFR decline, with secondary outcomes including major renal events, cardiovascular hospitalizations, mortality, and adverse drug reactions, plus exploratory links between biomarkers and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years old
* Diagnosed with chronic kidney disease (KDIGO stages 2-4)
* Life expectancy ≥12 months
* Available clinical and laboratory data in the electronic medical record

Exclusion Criteria:

* Current or recent renal replacement therapy or kidney transplantation
* End-stage renal disease
* Participation in interventional trials that may affect outcomes
* Allergy or intolerance to SGLT2i (for exposed cohort)

Where it's running

• Hospital Universitario de Salamanca
  Salamanca, Spain Recruiting

Study contacts

• Principal investigator: Carlos Martínez Salgado, PhD — University of Salamanca
• Study coordinator: Carlos Martínez Salgado, PhD
• Email: carlosms@usal.es
• Phone: +34616129633

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observational look at how Kremezin works in adults with advanced chronic kidney disease

  This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.

  Recruiting HK inno.N Corporation · Seoul · NCT07930169

• Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China

  This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 4 Novo Nordisk A/S · Fuyang, Anhui and 25 other locations · NCT07900438

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa

  This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.

  Recruiting University of Eastern Finland · Savonlinna · NCT07820800

• Arterial stiffness in children and young people with CKD and hypertension

  This study will test whether arterial stiffness is higher in children and young people with chronic kidney disease and high blood pressure compared with their peers, using a one-time assessment and follow-up for those with high BP.

  Recruiting King's College London · London, Greater London · NCT07768865

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.